Equities Analysts Offer Predictions for Bruker Co.’s Q3 2024 Earnings (NASDAQ:BRKR)

Bruker Co. (NASDAQ:BRKR) – Investment analysts at Zacks Research cut their Q3 2024 EPS estimates for shares of Bruker in a research report issued on Tuesday, August 27th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $0.62 per share for the quarter, down from their prior estimate of $0.75. The consensus estimate for Bruker’s current full-year earnings is $2.66 per share. Zacks Research also issued estimates for Bruker’s Q4 2024 earnings at $0.93 EPS, FY2024 earnings at $2.60 EPS, Q1 2025 earnings at $0.50 EPS, Q2 2025 earnings at $0.64 EPS, FY2025 earnings at $3.09 EPS, Q1 2026 earnings at $0.83 EPS, Q2 2026 earnings at $0.85 EPS and FY2026 earnings at $3.65 EPS.

A number of other research analysts have also recently issued reports on the company. The Goldman Sachs Group reduced their price objective on Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a research note on Tuesday, July 9th. Citigroup reduced their price objective on Bruker from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Wednesday, July 10th. Stifel Nicolaus reduced their price objective on Bruker from $81.00 to $77.00 and set a “hold” rating on the stock in a research note on Monday, May 20th. Bank of America reduced their price objective on Bruker from $95.00 to $90.00 and set a “buy” rating on the stock in a research note on Monday, May 20th. Finally, Jefferies Financial Group initiated coverage on Bruker in a research note on Monday, June 3rd. They issued a “buy” rating and a $85.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $81.40.

Bruker Stock Up 4.9 %

Shares of NASDAQ:BRKR opened at $67.59 on Thursday. The firm has a market capitalization of $9.82 billion, a PE ratio of 24.58, a price-to-earnings-growth ratio of 2.39 and a beta of 1.20. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.91 and a current ratio of 1.81. Bruker has a 52-week low of $53.79 and a 52-week high of $94.86. The firm has a fifty day moving average of $63.85 and a 200 day moving average of $74.78.

Bruker (NASDAQ:BRKR) last posted its earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.52. Bruker had a net margin of 13.38% and a return on equity of 27.31%. The business had revenue of $800.70 million for the quarter, compared to analysts’ expectations of $799.44 million. During the same period in the prior year, the company posted $0.50 EPS. The business’s revenue for the quarter was up 17.4% compared to the same quarter last year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 16th. Stockholders of record on Monday, September 2nd will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Friday, August 30th. This represents a $0.20 annualized dividend and a dividend yield of 0.30%. Bruker’s payout ratio is 7.27%.

Hedge Funds Weigh In On Bruker

A number of hedge funds have recently added to or reduced their stakes in the company. First Horizon Advisors Inc. grew its position in Bruker by 120.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after purchasing an additional 218 shares during the period. Rise Advisors LLC bought a new stake in shares of Bruker during the 1st quarter valued at $27,000. Neo Ivy Capital Management bought a new stake in shares of Bruker during the 4th quarter valued at $30,000. GAMMA Investing LLC bought a new stake in shares of Bruker during the 4th quarter valued at $33,000. Finally, Covestor Ltd grew its position in shares of Bruker by 139.1% during the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 210 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.